{
  "cik": 2012593,
  "cik_padded": "0002012593",
  "entityName": "Rapport Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-099360",
      "filed": "2026-03-10",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 616000.0,
        "cash": 52645000.0,
        "eps_diluted": -2.86,
        "free_cash_flow": -88089000.0,
        "net_income": -111483000.0,
        "operating_cash_flow": -87473000.0,
        "operating_income": -125099000.0,
        "stockholders_equity": 484653000.0,
        "total_assets": 512431000.0,
        "total_liabilities": 27778000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.05731523378582202,
        "roa_avg2y": -0.2694896079597372,
        "roa_period_end": -0.21755709549188082,
        "roe_avg2y": -0.28220686512758203,
        "roe_period_end": -0.23002643128176242
      }
    },
    {
      "accn": "0001193125-26-099360",
      "filed": "2026-03-10",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 2405000.0,
        "cash": 56805000.0,
        "eps_diluted": -3.78,
        "free_cash_flow": -67233000.0,
        "net_income": -78307000.0,
        "operating_cash_flow": -64828000.0,
        "operating_income": -83055000.0,
        "stockholders_equity": 305427000.0,
        "total_assets": 314933000.0,
        "total_liabilities": 9506000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.031123640018727878,
        "roa_avg2y": -0.33296907023616157,
        "roa_period_end": -0.24864653751750374,
        "roe_avg2y": -0.559749529116168,
        "roe_period_end": -0.2563853228431016
      }
    },
    {
      "accn": "0001193125-26-099360",
      "filed": "2026-03-10",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 1636000.0,
        "cash": 70169000.0,
        "eps_diluted": -23.1,
        "free_cash_flow": -28817000.0,
        "net_income": -34786000.0,
        "operating_cash_flow": -27181000.0,
        "operating_income": -36179000.0,
        "stockholders_equity": -25634000.0,
        "total_assets": 155423000.0,
        "total_liabilities": 14479000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.22381500807473798,
        "roe_avg2y": 1.9490138951142986
      }
    },
    {
      "accn": "0000950170-25-036828",
      "filed": "2025-03-11",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -10062000.0
      },
      "period_end": "2022-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-099360",
    "filed": "2026-03-10",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0002012593.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0002012593.json"
  },
  "ticker": "RAPP"
}